SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Section 1: Identification

Product name : Orbifloxacin Liquid Formulation

Manufacturer or supplier's details

Company : MSD
Address : 33 Whakatiki Street - Private Bag 908
          Upper Hutt - New Zealand
Telephone : +1-908-740-4000
Emergency telephone number : +1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

Section 2: Hazard identification

GHS Classification
Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Eye)

GHS label elements
Hazard pictograms : 
Signal word : Warning
Hazard statements : H361d Suspected of damaging the unborn child.
                   H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.
Precautionary statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>57-55-6</td>
<td>&gt;= 10 - &lt; 30</td>
</tr>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>&gt;= 3 - &lt; 10</td>
</tr>
<tr>
<td>Lactic acid</td>
<td>50-21-5</td>
<td>&gt;= 1 - &lt; 3</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>&gt;= 1 - &lt; 2</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents

### Section 8: Exposure controls/personal protection

#### Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>57-55-6</td>
<td>WES-TWA (particulate)</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WES-TWA (Vapour and particulates)</td>
<td>150 ppm 474 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>WES-Ceiling</td>
<td>2 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td></td>
<td>2 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

#### Engineering measures:
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

#### Personal protective equipment

**Respiratory protection:**
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type:**
Combined particulates and organic vapour type

**Hand protection:**
Chemical-resistant gloves
Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance: suspension

Colour: light brown

Odour: odourless

Odour Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: No data available

Evaporation rate: No data available

Flammability (solid, gas): Not applicable

Flammability (liquids): No data available

Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Vapour pressure: No data available

Relative vapour density: No data available

Relative density: No data available

Density: No data available

Solubility(ies)

Water solubility: No data available

Partition coefficient: n-octanol/water: No data available

Auto-ignition temperature: No data available

Decomposition temperature: No data available
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Viscosity
Viscosity, kinematic: No data available

Explosive properties: Not explosive

Oxidizing properties: The substance or mixture is not classified as oxidizing.

Molecular weight: No data available

Particle size: No data available

Section 10: Stability and reactivity

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes: Inhalation
              Skin contact
              Ingestion
              Eye contact

Acute toxicity
Not classified based on available information.

Components:

Propylene glycol:
Acute oral toxicity: LD50 (Rat): 22,000 mg/kg

Acute inhalation toxicity:
LC50 (Rat): > 44.9 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Orbifloxacin:
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular
LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular
LD50 (Rat): 233 mg/kg
Application Route: Intravenous
LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Lactic acid:
Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity
Remarks: Based on data from similar materials

Sodium hydroxide:
Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation
Not classified based on available information.

Product:
Species : Rabbit
Result : No skin irritation

Components:
Propylene glycol:
Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Orbifloxacin:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Lactic acid:
Species: Rabbit
Result: Skin irritation
Remarks: Based on data from similar materials

Sodium hydroxide:
Result: Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation
Not classified based on available information.

Product:
Species: Rabbit
Result: Mild eye irritation

Components:
Propylene glycol:
Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405

Orbifloxacin:
Species: Rabbit
Result: Mild eye irritation
Method: Draize Test

Lactic acid:
Species: Chicken eye
Remarks: Based on data from similar materials
Result: Irreversible effects on the eye

Sodium hydroxide:
Result: Irreversible effects on the eye
Remarks: Based on skin corrosivity.

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Version: 3.1
Revision Date: 27.08.2021
SDS Number: 785437-00012
Date of last issue: 01.10.2020
Date of first issue: 28.06.2016

Product:
Test Type: Magnusson-Kligman-Test
Exposure routes: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Components:

Propylene glycol:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative

Orbifloxacin:
Test Type: Maximisation Test
Exposure routes: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Lactic acid:
Test Type: Buehler Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials

Sodium hydroxide:
Test Type: Human repeat insult patch test (HRIPT)
Exposure routes: Skin contact
Result: negative

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Propylene glycol:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative
Orbifloxacin:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: equivocal
- Test Type: Mouse Lymphoma
  Result: positive
- Test Type: Chromosomal aberration
- Test system: Human lymphocytes
  Result: positive

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Mouse
  Cell type: Bone marrow
  Application Route: Intraperitoneal injection
  Result: negative
- Test Type: unscheduled DNA synthesis assay
  Species: Rat
  Cell type: Liver cells
  Application Route: Oral
  Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Lactic acid:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Method: OECD Test Guideline 471
  Result: negative
  Remarks: Based on data from similar materials
- Test Type: In vitro mammalian cell gene mutation test
  Method: OECD Test Guideline 476
  Result: negative
  Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
  Method: OECD Test Guideline 473
  Result: negative
  Remarks: Based on data from similar materials

Carcinogenicity:
Not classified based on available information.

Components:

Propylene glycol:
- Species: Rat
- Application Route: Ingestion
- Exposure time: 2 Years
- Result: negative
**Orbifloxacin:**

Species: Rat  
Application Route: Oral  
Exposure time: 2 Years  
NOAEL: 200 mg/kg body weight  
Result: negative

Species: Mouse  
Application Route: Oral  
Exposure time: 2 Years  
NOAEL: 200 mg/kg body weight  
Result: negative

**Lactic acid:**

Species: Rat  
Application Route: Ingestion  
Exposure time: 2 Years  
Result: negative  
Remarks: Based on data from similar materials

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:**

**Propylene glycol:**

Effects on fertility: Test Type: Two-generation reproduction toxicity study  
Species: Mouse  
Application Route: Ingestion  
Result: negative

Effects on foetal development: Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Orbifloxacin:**

Effects on fertility: Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 50 mg/kg body weight  
Early Embryonic Development: NOAEL: 50 mg/kg body weight  
Result: No adverse effects

Effects on foetal development: Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight  
Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high ma-
ternally toxic doses

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

Lactic acid:
Effects on foetal development: Test Type: Embryo-foetal development
Species: Mouse
Application Route: Ingestion
Result: negative

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Product:
Target Organs: Eye
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Product:
Species: Dog
NOAEL: 22.5 mg/kg
LOAEL: 37.5 mg/kg
Application Route: Oral
Exposure time: 30 Days
Symptoms: Gastrointestinal disturbance

Species: Dog
LOAEL: 75 mg/kg
Application Route: Oral
Exposure time: 10 Days
Symptoms: Salivation, Gastrointestinal disturbance, Vomiting

Species: Cat
LOAEL: 45 mg/kg
Application Route: Oral
Exposure time: 30 Days
Target Organs: Eye
Symptoms: Salivation, Lachrymation, Gastrointestinal disturbance, Liver disorders

**Components:**

**Propylene glycol:**
Species: Rat, male
NOAEL: >= 1,700 mg/kg
Application Route: Ingestion
Exposure time: 2 yr

**Orbifloxacin:**
Species: Rat
NOAEL: 20 mg/kg
LOAEL: 80 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: Testis, Liver, Kidney, spleen

Species: Mouse
NOAEL: 80 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 3 Months

Species: Juvenile dog
NOAEL: 50 mg/kg
LOAEL: 250 mg/kg
Application Route: Oral
Exposure time: 14 Days
Target Organs: Heart, Bone
Symptoms: Gastrointestinal disturbance
Remarks: mortality observed

Species: Juvenile dog
NOAEL: 2 mg/kg
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 90 Days
Target Organs: Bone
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 37.5 mg/kg
Application Route: Oral
Exposure time: 30 Days
Species: Cat
NOAEL: 7.5 mg/kg
LOAEL: 22.5 mg/kg
Application Route: Oral
Exposure time: 1 Months
Symptoms: Gastrointestinal disturbance

Lactic acid:
Species: Rat
NOAEL: > 100 mg/kg
Application Route: Ingestion
Exposure time: 13 Weeks
Remarks: Based on data from similar materials

Species: Rat
LOAEL: 886 mg/kg
Application Route: Skin contact
Exposure time: 13 Weeks

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Orbifloxacin:
Ingestion: Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitisation.

Section 12: Ecological information

Ecotoxicity

Components:

Propylene glycol:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l
Exposure time: 7 d

Toxicity to microorganisms: NOEC (Pseudomonas putida): > 20,000 mg/l
Exposure time: 18 h
### Lactic acid:

**Toxicity to fish**: LC50 (Danio rerio (zebra fish)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: Based on data from similar materials

**Toxicity to daphnia and other aquatic invertebrates**: EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: Based on data from similar materials

**Toxicity to algae/aquatic plants**: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

**Toxicity to microorganisms**: EC50: > 10 - 100 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209  
Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

**Propylene glycol**:  
Biodegradability: Result: Readily biodegradable.  
Biodegradation: 98.3 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F

**Lactic acid**:  
Biodegradability: Result: Not readily biodegradable.  
Remarks: Based on data from similar materials

### Bioaccumulative potential

#### Components:

**Propylene glycol**:  
Partition coefficient: n-octanol/water: log Pow: -1.07  

**Lactic acid**:  
Partition coefficient: n-octanol/water: log Pow: -0.62
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Mobility in soil
No data available

Other adverse effects
No data available

Section 13: Disposal considerations

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR
UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code
UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
UN number : Not applicable
Proper shipping name : Not applicable
SAFETY DATA SHEET

Orbifloxacin Liquid Formulation

Version: 3.1
Revision Date: 27.08.2021
SDS Number: 785437-00012
Date of last issue: 01.10.2020
Date of first issue: 28.06.2016

Class: Not applicable
Subsidiary risk: Not applicable
Packing group: Not applicable
Labels: Not applicable
Hazchem Code: Not applicable

Special precautions for user
Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

Section 16: Other information

Further information


Date format: dd.mm.yyyy

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
NZ OEL: New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / C: Ceiling limit
NZ OEL / WES-TWA: Workplace Exposure Standard - Time Weighted average
NZ OEL / WES-Ceiling: Workplace Exposure Standard - Ceiling

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NZ / EN